BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9783591)

  • 1. Amifostine in reducing cisplatin toxicity.
    Markman M
    Semin Oncol; 1998 Oct; 25(5):522-4. PubMed ID: 9783591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
    Kurbacher CM; Mallmann PK
    Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
    Selvaggi G; Belani CP
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
    Sastry J; Kellie SJ
    Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
    Gallegos-Castorena S; Martínez-Avalos A; Mohar-Betancourt A; Guerrero-Avendaño G; Zapata-Tarrés M; Medina-Sansón A
    Pediatr Hematol Oncol; 2007 Sep; 24(6):403-8. PubMed ID: 17710657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
    Thongprasert S; Chewaskulyong B
    J Med Assoc Thai; 2004 Oct; 87(10):1162-7. PubMed ID: 15560691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of the cytoprotectant amifostine.
    Lindemann K
    Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.
    Jones RB; Stockerl-Goldstein KE; Klein J; Murphy J; Blume KG; Dansey R; Martinez C; Matthes S; Nieto Y
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):276-82. PubMed ID: 15077226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
    Marcu LG
    Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurologic protection by amifostine.
    DiPaola RS; Schuchter L
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential for use of amifostine in cervical cancer.
    Small W
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):34-7. PubMed ID: 12577241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
    Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
    Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
    Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
    Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amifostine.
    Viele C
    Clin J Oncol Nurs; 1999 Jul; 3(3):128, 131. PubMed ID: 10690046
    [No Abstract]   [Full Text] [Related]  

  • 17. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
    Mehta V
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
    Asna N; Lewy H; Ashkenazi IE; Deutsch V; Peretz H; Inbar M; Ron IG
    Life Sci; 2005 Mar; 76(16):1825-34. PubMed ID: 15698860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase.
    Zhang J; Wang X; Lu H
    Cancer Lett; 2008 Feb; 260(1-2):127-36. PubMed ID: 18039557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
    Capizzi RL; Oster W
    Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.